Impact of Ixekizumab Treatment on Itch and Psoriasis Area and Severity Index in Patients with Moderate-to-Severe Plaque Psoriasis: An Integrated Analysis of Two Phase III Randomized Studies
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2190-9172
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Impact of Ixekizumab Treatment on Itch and Psoriasis Area and Severity Index in Patients with Moderate-to-Severe Plaque Psoriasis: An Integrated Analysis of Two Phase III Randomized Studies ; volume:8 ; number:4 ; day:21 ; month:11 ; year:2018 ; pages:621-637 ; date:12.2018
Dermatology and therapy ; 8, Heft 4 (21.11.2018), 621-637, 12.2018
- Creator
-
Yosipovitch, Gil
Reich, Adam
Steinhoff, Martin
Beselin, Anke
Kent, Toby
Dossenbach, Martin
Berggren, Lovisa
Henneges, Carsten
Luger, Thomas
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s13555-018-0267-9
- URN
-
urn:nbn:de:101:1-2019010721231877977123
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:59 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Yosipovitch, Gil
- Reich, Adam
- Steinhoff, Martin
- Beselin, Anke
- Kent, Toby
- Dossenbach, Martin
- Berggren, Lovisa
- Henneges, Carsten
- Luger, Thomas
- SpringerLink (Online service)
Other Objects (12)
Ixekizumab (Plaque Psoriasis) : Nutzenbewertung gemäß § 35a SGB V
Ixekizumab (Plaque Psoriasis) : Addendum zum Auftrag A17-07
Treatment Persistence of Ixekizumab in Adults with Moderate-to-Severe Plaque Psoriasis Participating in the Canadian Patient Support Program
Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Safety and Efficacy of Ixekizumab in Chinese Adults with Moderate-to-Severe Plaque Psoriasis: A Prospective, Multicenter, Observational Study
Ixekizumab (Plaque-Psoriasis bei Kindern und Jugendlichen) : Nutzenbewertung gemäß § 35a SGB V
Ixekizumab (Plaque-Psoriasis bei Kindern und Jugendlichen) : Addendum zum Auftrag A20-65
Ixekizumab (Plaque-Psoriasis bei Kindern und Jugendlichen) : Nutzenbewertung gemäß § 35a SGB V
A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
Long-Term Effectiveness and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Five-Year Multicenter Retrospective Study—IL PSO (Italian Landscape Psoriasis)
Ixekizumab : ein zielgerichteter Interleukin-17A-Inhibitor bei Erwachsenen mit mitttelschwerer bis schwerer Plaque-Psoriasis
Ixekizumab: an alternative for HIV-positive psoriasis patients
Ixekizumab (Plaque Psoriasis) : Nutzenbewertung gemäß § 35a SGB V
Ixekizumab (Plaque Psoriasis) : Addendum zum Auftrag A17-07
Treatment Persistence of Ixekizumab in Adults with Moderate-to-Severe Plaque Psoriasis Participating in the Canadian Patient Support Program
Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Safety and Efficacy of Ixekizumab in Chinese Adults with Moderate-to-Severe Plaque Psoriasis: A Prospective, Multicenter, Observational Study
Ixekizumab (Plaque-Psoriasis bei Kindern und Jugendlichen) : Nutzenbewertung gemäß § 35a SGB V
Ixekizumab (Plaque-Psoriasis bei Kindern und Jugendlichen) : Addendum zum Auftrag A20-65
Ixekizumab (Plaque-Psoriasis bei Kindern und Jugendlichen) : Nutzenbewertung gemäß § 35a SGB V
A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
Long-Term Effectiveness and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Five-Year Multicenter Retrospective Study—IL PSO (Italian Landscape Psoriasis)
Ixekizumab : ein zielgerichteter Interleukin-17A-Inhibitor bei Erwachsenen mit mitttelschwerer bis schwerer Plaque-Psoriasis
Ixekizumab: an alternative for HIV-positive psoriasis patients
Ixekizumab (Plaque Psoriasis) : Nutzenbewertung gemäß § 35a SGB V
Ixekizumab (Plaque Psoriasis) : Addendum zum Auftrag A17-07
Treatment Persistence of Ixekizumab in Adults with Moderate-to-Severe Plaque Psoriasis Participating in the Canadian Patient Support Program
Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Safety and Efficacy of Ixekizumab in Chinese Adults with Moderate-to-Severe Plaque Psoriasis: A Prospective, Multicenter, Observational Study
Ixekizumab (Plaque-Psoriasis bei Kindern und Jugendlichen) : Nutzenbewertung gemäß § 35a SGB V
Ixekizumab (Plaque-Psoriasis bei Kindern und Jugendlichen) : Addendum zum Auftrag A20-65
Ixekizumab (Plaque-Psoriasis bei Kindern und Jugendlichen) : Nutzenbewertung gemäß § 35a SGB V
A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
Long-Term Effectiveness and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Five-Year Multicenter Retrospective Study—IL PSO (Italian Landscape Psoriasis)
Ixekizumab : ein zielgerichteter Interleukin-17A-Inhibitor bei Erwachsenen mit mitttelschwerer bis schwerer Plaque-Psoriasis